Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases

Abstract : Background There has been limited evaluation of the association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases (IBD). Aim To perform a systematic review and meta-analysis to evaluate the potential role of therapeutic drug monitoring (TDM) for vedolizumab. Methods Through a systematic literature search through 28 February 2019, we identified five cohort studies (558 patients, 42% with ulcerative colitis) reporting the association between vedolizumab trough concentration and clinical outcomes in patients with IBD. We calculated mean difference (MD) in vedolizumab trough concentration in patients achieving vs not achieving clinical outcomes, and qualitatively synthesized thresholds associated with favourable outcomes. Results In patients with UC, median vedolizumab trough concentrations were consistently higher in patients achieving clinical remission (median, 14.3 mu g/mL vs 10.5 mu g/mL; MD, 5.1 mu g/mL, 95% CI, 2.8-7.4) or endoscopic remission (median, 13.0 mu g/mL vs 9.7; MD, 5.1 mu g/mL, 95% CI, 2.2-7.9). In patients with CD, there was no significant difference in median vedolizumab trough concentrations in patients achieving vs not achieving clinical remission (MD, 2.0 mu g/mL; 95% CI, -0.5 to 4.5) or endoscopic remission (MD, 3.6 mu g/mL; 95% CI, -1.4 to 8.6). In patients with UC, week 6 vedolizumab trough concentrations >= 18.5-20.8 mu g/mL, and maintenance trough concentrations >= 9.0-12.6 mu g/mL were associated with favourable clinical outcomes. Antibodies to vedolizumab were reported in 1.7%-3.0% patients on maintenance therapy. Conclusion Based on meta-analysis, patients with UC who achieve endoscopic and clinical remission have significantly higher vedolizumab trough concentration during maintenance therapy. Vedolizumab trough concentration >20 mu g/mL at week 6, and >12 mu g/mL during maintenance may be associated with better outcomes, though cause-effect relationship remains unclear. Prospective studies on reactive and proactive therapeutic drug monitoring of vedolizumab (vs empiric dose escalation) are warranted.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal-u-picardie.archives-ouvertes.fr/hal-03552289
Contributeur : Louise Dessaivre Connectez-vous pour contacter le contributeur
Soumis le : mercredi 2 février 2022 - 11:18:55
Dernière modification le : vendredi 25 mars 2022 - 18:12:15

Lien texte intégral

Identifiants

Collections

Citation

Siddharth Singh, Parambir S. Dulai, Niels Vande Casteele, Robert Battat, Mathurin Fumery, et al.. Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, Wiley, 2019, 50 (8), pp.848-857. ⟨10.1111/apt.15484⟩. ⟨hal-03552289⟩

Partager

Métriques

Consultations de la notice

2